Analysis of expression levels of IL-17 and IL-34 and influencing factors for prognosis in patients with lupus nephritis

Cheng,Yanna; Yang,Xiaojuan; Zhang,Xijun; An,Zhi

doi:10.3892/etm.2019.7168

Analysis of expression levels of IL-17 and IL-34 and influencing factors for prognosis in patients with lupus nephritis

Authors:
- Yanna Cheng
- Xiaojuan Yang
- Xijun Zhang
- Zhi An
View Affiliations

Affiliations: Department of Nephrology, Yanan University Affiliated Hospital, Yanan, Shaanxi 716000, P.R. China, Department of Nephrology, Yanan People's Hospital, Yanan, Shaanxi 716000, P.R. China
Published online on: January 14, 2019 https://doi.org/10.3892/etm.2019.7168
Pages: 2279-2283
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression levels of interleukin-17 (IL-17) and IL-34 was investigated to analyze the influencing factors for prognosis in patients with lupus nephritis (LN). Clinical data of 45 patients (LN group) treated and diagnosed with LN via renal biopsy in Yanan University Affiliated Hospital from October 2010 to October 2012 and 50 healthy subjects (control group) were analyzed retrospectively. Levels of serum IL-17 and IL-34 were detected via enzyme-linked immunosorbent assay. Correlations of serum IL-17 and IL-34 with urinary protein in LN patients were analyzed via Pearson correlation analysis. Univariate survival analysis was performed using the Kaplan-Meier method, and multivariate analysis was performed for LN prognosis using the Cox proportional hazards model. Levels of serum IL-34 and IL-17 in patients in LN group were significantly higher than those in control group (P<0.001). Serum IL-17 and IL-34 in LN patients were positively correlated with urinary protein (r= 0.436 and 0.714, P<0.05). Adverse factors affecting the prognosis of 45 LN patients including age, hemoglobin, platelet, blood uric acid, urinary protein, IL-17 and IL-34, showing statistically significant differences (P<0.05). Age, hemoglobin, blood uric acid, urinary protein, IL-17 and IL-34 were independent risk factors for poor prognosis of LN (P<0.05). The inflammatory factors IL-17 and IL-34 are highly expressed in the serum of LN patients. Levels of serum IL-17 and IL-34 in LN patients have positive correlations with urinary protein. Results of univariate and multivariate Cox regression analyses reveal that age, hemoglobin, blood uric acid, urinary protein, IL-17 and IL-34 are independent risk factors for poor prognosis of LN. IL-17 and IL-34 can therefore serve as effective indexes for clinical diagnosis, treatment and prognosis of LN.

View Figures

View References

1	Rönnblom L and Pascual V: The innate immune system in SLE: Type I interferons and dendritic cells. Lupus. 17:394–399. 2008. View Article : Google Scholar : PubMed/NCBI
2	Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV and Diamond B: Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 203:2157–2164. 2006. View Article : Google Scholar : PubMed/NCBI
3	Faurschou M, Starklint H, Halberg P and Jacobsen S: Prognostic factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 33:1563–1569. 2006.PubMed/NCBI
4	Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC and Ritchie S: Serial renal biopsy in systemic lupus erythematosus. J Rheumatol. 27:2822–2826. 2000.PubMed/NCBI
5	Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M and Font J: Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 85:95–104. 2006. View Article : Google Scholar : PubMed/NCBI
6	Heimovski FE, Simioni JA and Skare TL: Systemic lupus erythematosus and Raynaud's phenomenon. An Bras Dermatol. 90:837–840. 2015. View Article : Google Scholar : PubMed/NCBI
7	D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, Khamashta MA and Hughes GR: Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: Good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 31:280–285. 2004.PubMed/NCBI
8	Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, et al: Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 320:807–811. 2008. View Article : Google Scholar : PubMed/NCBI
9	Foucher ED, Blanchard S, Preisser L, Garo E, Ifrah N, Guardiola P, Delneste Y and Jeannin P: IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ. PLoS One. 8:e560452013. View Article : Google Scholar : PubMed/NCBI
10	Chalmers SA, Chitu V, Ramanujam M and Putterman C: Therapeutic targeting of macrophages in lupus nephritis. Discov Med. 20:43–49. 2015.PubMed/NCBI
11	Roussel L, Houle F, Chan C, Yao Y, Bérubé J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, et al: IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol. 184:4531–4537. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, et al: Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep. 37:81–85. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, et al: Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 9:166–175. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sprangers B, Monahan M and Appel GB: Diagnosis and treatment of lupus nephritis flares - an update. Nat Rev Nephrol. 8:709–717. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW and Lau CS: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 50:2559–2568. 2004. View Article : Google Scholar : PubMed/NCBI
16	Saxena R, Mahajan T and Mohan C: Lupus nephritis: Current update. Arthritis Res Ther. 13:2402011. View Article : Google Scholar : PubMed/NCBI
17	Balow JE, Waldman M and Austin HA: Lupus nephritis. Therapy in Nephrology & Hypertension. Saunders; Philadelphia, PA: pp. 157–171. 2008, View Article : Google Scholar
18	Bethunaickan R, Berthier CC, Zhang W, Kretzler M and Davidson A: Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One. 8:e774892013. View Article : Google Scholar : PubMed/NCBI
19	Susianti H, Iriane VM, Dharmanata S, Handono K, Widijanti A, Gunawan A and Kalim H: Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology. 22:65–71. 2015. View Article : Google Scholar : PubMed/NCBI
20	Menke J, Rabacal WA, Byrne KT, Iwata Y, Schwartz MM, Stanley ER, Schwarting A and Kelley VR: Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol. 20:2581–2592. 2009. View Article : Google Scholar : PubMed/NCBI
21	Shen K, Yu Y, Tang Z, Liu Z and Li L: The prognosis of biopsy-proven lupus nephritis in Chinese patients: Long term follow-up of 86 cases. Chin Med J (Engl). 110:502–507. 1997.PubMed/NCBI
22	Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF and Berland Y: Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 60:2215–2221. 2001. View Article : Google Scholar : PubMed/NCBI
23	Nee R, Jindal RM, Little D, Ramsey-Goldman R, Agodoa L, Hurst FP and Abbott KC: Racial differences and income disparities are associated with poor outcomes in kidney transplant recipients with lupus nephritis. Transplantation. 95:1471–1478. 2013. View Article : Google Scholar : PubMed/NCBI
24	Yap DY, Tang CS, Ma MK, Lam MF and Chan TM: Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 27:3248–3254. 2012. View Article : Google Scholar : PubMed/NCBI
25	Sánchez-Lozada LG, Tapia E, López-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J and Franco M: Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol. 292:F1238–F1244. 2007. View Article : Google Scholar : PubMed/NCBI
26	Wu T, Fu Y, Brekken D, Yan M, Zhou XJ, Vanarsa K, Deljavan N, Ahn C, Putterman C and Mohan C: Urine proteome scans uncover total urinary protease, PGDS, SAP and SOD as potential markers of lupus nephritis. J Immunol. 184:2183–2193. 2010. View Article : Google Scholar : PubMed/NCBI